Exhibit 99.1 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS AS OF AND FOR THE SIX MONTHS ENDED JUNE 30, 2021 AND 2020 NLS PHARMACEUTICS LTD. UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS | Unaudited Interim Condensed Balance Sheets as of June 30, 2021 and December 31, 2020 | 3 | | --- | --- | | Unaudited Interim Condensed Statements of Operating and Comprehensive Loss for the Six Months Ended June 30, 2021 | 4 | | and 2020 | | | Unaudited Interim Condensed Statements of Changes i ...

FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No.: 001-39957 NLS PHARMACEUTICS LTD. (Exact name of registrant ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of May 2021 Commission file number: 001-39957 NLS PHARMACEUTICS LTD. (Translation of registrant's name into English) Alter Postplatz 2 CH-6370 Stans, Switzerland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F ...